Thursday, January 9, 2014

Danish Mega Study - 1.2 Million Subjects - Reveals Increased Cardio Vascular Adverse Events From Antipsychotics In Elderly

First up; newswire;
As Risperdal Lawsuits Move Forward, Bernstein Liebhard LLP Notes New Study Finding Increased Risk of Heart Events in Elderly Treated with Antipsychotic Drugs

New York, New York (PRWEB) January 07, 2014
As Risperdal lawsuits, ( including many that allege a connection between the use of Risperdal and gynecomastia (male breast growth), continue to move forward in courts around the U.S., a new study has found that elderly people treated with Risperdal and other antipsychotic drugs may face a substantially increased risk for a major adverse cardiovascular disease event. The study, which was based on a review of Danish health records involving more than 1 million people, found that the risk was highest during the first month of treatment, and that it remained elevated among patients who were 70 or older. The research was presented in November at the American Heart Association scientific sessions in Dallas.*

Read more:

Batting Second;
Clinical Psychiatry News;

Antipsychotics boosted CVD events in elderly

DALLAS – Elderly patients who started treatment with an antipsychotic drug had a substantially increased risk for a major adverse cardiovascular disease event, especially during the first month on treatment, according to Danish national records from more than 1 million people.
The risk remained elevated even when the analysis focused on elderly people who were aged 70 years or older and were without cardiovascular disease or dementia at the time of their first use of an antipsychotic medication, Dr. Charlotte Andersson and her associates reported in a poster at the American Heart Association scientific sessions.
Treatment was linked with a significantly increased rate of major adverse cardiovascular events (MACE) at some time during follow-up for all eight antipsychotic drugs studied in detail: haloperidol (Haldol), flupentixol (Fluanxol), chlorprothixene, levomepromazine (Nozinan), quetiapine (Seroquel), risperidone (Risperdal), olanzapine, and ziprasidone (Geodon), reported Dr. Andersson, a researcher at Gentofte Hospital in Copenhagen. The MACE association was relatively weak for ziprasidone, but it was robust for the other seven agents.

Third Batter Steps up, Strikes Out, and, . . . they're still on the market because "Industry Profits Must Continue".
Presentation Abstract
Session:APS.211.04-Cardiovascular Implications of Noncardiac Medications
Presentation:16650 - Association of Selected Anti-Psychotic Agents With Major Adverse Cardiovascular Events in Elderly Individuals: A Danish Nationwide Cohort Study
Location:Hall F, Core 2, Poster Board: 2110
Specialty:+211. Epidemiology and Population Studies
Authors:Marie Sahlberg, Gentofte Hosp, Hellerup, Denmark; Ellen Holm, Nykøbing-Falster Hosp, Nykobing Falster, Denmark; Gunnar H Gislason, Gentofte Hosp, Hellerup, Denmark; Christian Torp-Pedersen, Inst of Health, Science and Technology, Aalborg, Denmark; Charlotte Andersson, Gentofte Hosp, Hellerup, Denmark
Concerns have been raised about the safety of treatment with antipsychotic agents (APS) in elderly people with dementia, but this area is still insufficiently investigated. We studied the risks of major adverse cardiovascular events (MACE; non-fatal myocardial infarction, non-fatal stroke or cardiovascular death) associated with use of different APS in elderly using nationwide Danish data.
All individuals in Denmark aged 70 years or older between 1997 and 2009 who had not used APS prior to study baseline were included. Exposure to APS was assessed through claimed prescriptions from pharmacies. Adjusted relative risks (RR) associated with exposure to APS were calculated by time-dependent Poisson regression models.

We included 1,235,869 individuals of which 100,140 (8,1%) used APS at some point. For all agents, we found a highly increased RR of MACE during the first month after initiation, Figure. Long-term use (i.e.> 1 year) was however still associated with approximately 2-fold increase in RR for the majority of agents. The majority of agents further demonstrated a dose-dependent increase in RR and higher RR associated with long-term use among individuals without prevalent cardiovascular disease or dementia.

continue reading presentation abstract, . . .

How much more money and How many more lives were wasted 'Investigating' these junk, killer drugs yet again, as Govt. funded make work?

No comments: